Greater Sydney Area
Dr Paul Kelly is a Founding Partner of OneVentures and leads the Healthcare strategy and investments of the fund. Starting with his background as an Australian Physician and Endocrinologist, Paul has a long history of biotechnology entrepreneurship, from developing innovation to commercialising at scale. Having returned to Australia in 2010 (after 15 years in the UK and US), he is dedicated to improving healthcare and treatment options for patients across the world. He lives and invests guided by his vision for a better future: through innovation, collaborative effort, and determination.
OneVentures is a later-stage venture capital firm focused on scaling technology and healthcare companies through growth equity and credit. Since 2010, we've launched seven funds, investing in transformative founders who are building for the future. We leverage our operational expertise and provide hands-on guidance to support businesses through their strategic growth phases.
Australia’s Economic Accelerator (AEA) is a research funding program designed to shift the dial on Australian research by supporting the translation and commercialisation of our world leading research in the university sector.
BiVACOR Inc is a medical device company developing an implantable biventricular device total heart for patients with severe heart failure. Daniel Timms, PhD, is the inventor and founder of BiVACOR, Inc. is graduate of the Queensland University of Technology. DR Timms invented the BiVacor Total Artificial Heart (TAH); a total artificial heart designed to take over the complete function of a patient’s failing heart.
Prota Therapeutics is a company developing a oral immunotherapy platform technology for the treatment of food allergies in children. OneVentures led the initial financing of the company and its spin out from Murdoch Childrens Research Institute in 2016.
Garvan's mission is to make significant contributions to medical research that will change the directions of science and medicine and have major impacts on human health. Garvan strives to enhance and develop research programs that combine fundamental science with strong clinical interactions